Bladder-sparing therapy for bladder cancer with drug combination
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies a combination of two drugs for bladder cancer that has not spread beyond the bladder. It aims to help patients who want to avoid bladder removal surgery, potentially preserving their bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have bladder cancer that has grown into the bladder muscle but has not spread to lymph nodes or other organs.
- Your cancer cells show a certain protein (HER2) at a high level on a biopsy test.
- You have chosen not to have surgery to remove your bladder.
- Your overall health is good enough for the study treatments.
- You have not had radiation therapy to the bladder before.
- You are not pregnant or breastfeeding.
- You have not had other cancer treatments that could interfere with this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This study tests a combination of two drugs given directly into the bladder for a type of early-stage bladder cancer that has a specific protein marker called HER2. The goal is to see if the combination helps prevent the cancer from coming back.
This trial tests a combination of two drugs for people with muscle-invasive bladder cancer who cannot receive cisplatin chemotherapy. The drugs target cancer cells and may help the body's immune system fight the tumor.
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.